KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash from Financing Activities (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Cash from Financing Activities for 8 consecutive years, with $21.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 16953.54% to $21.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.4 million through Dec 2025, up 12515.35% year-over-year, with the annual reading at $30.4 million for FY2025, 12515.35% up from the prior year.
  • Cash from Financing Activities hit $21.7 million in Q4 2025 for Adaptive Biotechnologies, up from $1.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $125.5 million in Q3 2022 to a low of $6000.0 in Q4 2022.
  • Historically, Cash from Financing Activities has averaged $9.6 million across 5 years, with a median of $1.6 million in 2025.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 99.99% in 2023 and later soared 16953.54% in 2025.
  • Year by year, Cash from Financing Activities stood at $3.3 million in 2021, then tumbled by 99.82% to $6000.0 in 2022, then skyrocketed by 1350.0% to $87000.0 in 2023, then surged by 45.98% to $127000.0 in 2024, then skyrocketed by 16953.54% to $21.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ADPT at $21.7 million in Q4 2025, $1.7 million in Q3 2025, and $1.6 million in Q2 2025.